TY - JOUR AU - M Galli, AU - F Elice, AU - C Crippa, AU - B Comotti, AU - F Rodeghiero, AU - T Barbui, PY - 2004/09/01 Y2 - 2024/03/28 TI - Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma JF - Haematologica JA - haematol VL - 89 IS - 9 SE - Letters to the Editor DO - 10.3324/%x UR - https://haematologica.org/article/view/3228 SP - 1141-1142 AB - Among 199 patients treated with thalidomide for multiple myeloma, four thromboses occurred in 49 cases during erythropoietin therapy (prevalence 8.1%; annual rate 7.25%), and another 14 events occurred in patients not on erythropoietin (9.3%; 7.56%). Thus, erythropoietin would seem not to increase the risk of thrombosis of myeloma patients receiving thalidomide. ER -